# Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery

> **NCT02573610** · PHASE3 · COMPLETED · sponsor: **Santen Pharmaceutical Co., Ltd.** · enrollment: 576 (actual)

## Conditions studied

- Cataract Surgery

## Interventions

- **DRUG:** DE-108
- **DRUG:** Levofloxacin 0.5%

## Key facts

- **NCT ID:** NCT02573610
- **Lead sponsor:** Santen Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-21
- **Primary completion:** 2017-03-31
- **Final completion:** 2017-03-31
- **Target enrollment:** 576 (ACTUAL)
- **Last updated:** 2017-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573610, "Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02573610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*